GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (NAS:ABEO) » Definitions » E10

Abeona Therapeutics (Abeona Therapeutics) E10 : $-118.87 (As of Mar. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Abeona Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-1.160. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-118.87 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 15.60% per year. During the past 5 years, the average E10 Growth Rate was 25.60% per year. During the past 10 years, the average E10 Growth Rate was 33.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Abeona Therapeutics was 51.70% per year. The lowest was 3.80% per year. And the median was 13.20% per year.

As of today (2024-05-24), Abeona Therapeutics's current stock price is $4.05. Abeona Therapeutics's E10 for the quarter that ended in Mar. 2024 was $-118.87. Abeona Therapeutics's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Abeona Therapeutics was 0.19. The lowest was 0.11. And the median was 0.17.


Abeona Therapeutics E10 Historical Data

The historical data trend for Abeona Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics E10 Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -277.28 -194.65 -175.58 -104.28 -116.83

Abeona Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -127.18 -133.55 -128.95 -116.83 -118.87

Competitive Comparison of Abeona Therapeutics's E10

For the Biotechnology subindustry, Abeona Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Shiller PE Ratio falls into.



Abeona Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Abeona Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.16/131.7762*131.7762
=-1.160

Current CPI (Mar. 2024) = 131.7762.

Abeona Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -631.500 100.560 -827.537
201409 -103.750 100.428 -136.135
201412 -15.815 99.070 -21.036
201503 -2.500 99.621 -3.307
201506 -4.000 100.684 -5.235
201509 -4.750 100.392 -6.235
201512 -1.500 99.792 -1.981
201603 -4.250 100.470 -5.574
201606 -5.000 101.688 -6.479
201609 -2.000 101.861 -2.587
201612 -4.750 101.863 -6.145
201703 -3.250 102.862 -4.164
201706 -5.250 103.349 -6.694
201709 -3.250 104.136 -4.113
201712 -4.750 104.011 -6.018
201803 -5.500 105.290 -6.884
201806 -6.500 106.317 -8.057
201809 -8.500 106.507 -10.517
201812 -9.000 105.998 -11.189
201903 -9.750 107.251 -11.980
201906 -12.250 108.070 -14.937
201909 -8.750 108.329 -10.644
201912 -7.250 108.420 -8.812
202003 -13.000 108.902 -15.731
202006 -3.500 108.767 -4.240
202009 -2.000 109.815 -2.400
202012 -4.250 109.897 -5.096
202103 -4.250 111.754 -5.011
202106 -3.930 114.631 -4.518
202109 -1.800 115.734 -2.049
202112 -11.250 117.630 -12.603
202203 -3.800 121.301 -4.128
202206 -1.360 125.017 -1.434
202209 -1.000 125.227 -1.052
202212 -0.402 125.222 -0.423
202303 -0.540 127.348 -0.559
202306 -0.920 128.729 -0.942
202309 -0.480 129.860 -0.487
202312 -0.640 129.419 -0.652
202403 -1.160 131.776 -1.160

Add all the adjusted EPS together and divide 10 will get our e10.


Abeona Therapeutics  (NAS:ABEO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Abeona Therapeutics was 0.19. The lowest was 0.11. And the median was 0.17.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Abeona Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics (Abeona Therapeutics) Business Description

Traded in Other Exchanges
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.
Executives
Mark Alvino director C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019
Michael Amoroso officer: Chief Operating Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Vishwas Seshadri director, officer: Chief Executive Officer 64 STRYKER COURT, BRIDGEWATER NJ 08807
Leila Alland director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Christine Berni Silverstein officer: Chief Financial Officer C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Joseph Walter Vazzano officer: Chief Financial Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Brendan M. O'malley officer: SVP, General Counsel 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Adage Capital Partners, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Management, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners Gp, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Edward Carr officer: Vice President, Controller 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Todd Wider director 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219

Abeona Therapeutics (Abeona Therapeutics) Headlines